Pharmaceutical Industry News Roundup: May 2020

by Staff Writer

Each month, MMS shares key stories on the evolution of the pharmaceutical industry. Here is a selection from May:

Coronavirus (COVID-19) Update: FDA Collaborations Promote Rigorous Analyses of Real-World Data to Inform Pandemic ResponseU.S. Food & Drug Administration (FDA)

The FDA recently announced its effort to use diverse streams of data to understand and respond to COVID-19. The government agency entered an agreement with Aetion to collaborate on analytical techniques to answer urgent COVID-19-related questions.

Visit the FDA newsroom for the latest updates

CDC to Launch Massive Population-based Antibody Testing for SARS-CoV-2BioSpace

The Centers for Disease Control and Prevention (CDC) is about to launch a 25-city SARS-CoV-2 antibody study in June or July. The massive study will test 325,000 people to learn more about the virus.

Gail Dutton has the full story

The 2019 Avoca State of the Industry Report—The Avoca Group

The Avoca Group—a life sciences consulting firm—released its 2019 “State of the Industry” report. This report focuses on clinical outsourcing spend and key relationship measures.

Access the report here

The Impacts of COVID-19 on Clinical Trial Transparency and Document Disclosure PHUSE CTT ProjectPHUSE

MMS experts Barb Rusin, Senior Regulatory Compliance Manager, and Kasim McLain, Manager, Transparency recently provided their insights in a PHUSE blog examining the impacts of COVID-19 on clinical study disclosure and transparency. This blog outlines what may require immediate action.

Read the blog article via PHUSE

University of Michigan School of Information Invites MMS Holdings Executive Kelly J. Hill to Join External Advisory BoardMMS

MMS Executive Director of Global Business Operations and Strategy Kelly J. Hill has accepted an invitation to join the University of Michigan School of Information (UMSI) External Advisory Board (EAB).Serving on a three-year term, Hill will join a group of internationally-recognized experts who consult with the UMSI Dean on a wide range of strategic topics, including research initiatives, curriculum innovation, and social impact.

Read the full story

Webinar: Recommended Changes for Pharma Companies in Response to COVID-19—MMS Holdings

In this complementary webinar, MMS regulatory experts Barbara Rusin, Senior Regulatory Compliance Manager, and Ben Kaspar, Global Regulatory Affairs Manager, discuss changes pharmaceutical companies should consider implementing in response to COVID-19. They focus not only on changes to study-related documents recommended by regulatory authorities, but other aspects affecting trials.

Register today

< Back to MMS Blog